Status:
COMPLETED
Zinc Supplements in Lowering Cadmium Levels in Smokers
Lead Sponsor:
Wake Forest University Health Sciences
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Bladder Cancer
Cervical Cancer
Eligibility:
All Genders
21-120 years
Phase:
PHASE2
Brief Summary
RATIONALE: Zinc supplements may lower cadmium levels in smokers and may help prevent DNA damage. PURPOSE: This clinical trial is studying how well zinc supplements work in lowering cadmium levels in ...
Detailed Description
OBJECTIVES: * Determine whether zinc supplements reduce cadmium levels in smokers. * Measure serum levels of cotinine (a biomarker of smoking), zinc (a marker of compliance), and cadmium (the depende...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Currently smoking ≥ 1 pack (20 cigarettes) per day
- Baseline cadmium level ≥ 0.5 μg/L
- PATIENT CHARACTERISTICS:
- Negative pregnancy test
- Fertile patients must use effective contraception
- No known gastrointestinal upset due to zinc vitamins or lozenges
- PRIOR CONCURRENT THERAPY:
- At least 2 weeks since prior and no other concurrent vitamins and zinc supplements
Exclusion
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00376987
Start Date
December 1 2003
End Date
June 1 2015
Last Update
May 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States, 27157-1096